Annabel Samimy
Stock Analyst at Stifel
(4.49)
# 330
Out of 4,562 analysts
54
Total ratings
48.98%
Success rate
37.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVNC Revance Therapeutics | Maintains: Buy | $24 → $20 | $6.55 | +205.34% | 3 | Aug 9, 2024 | |
| KMDA Kamada | Initiates: Buy | $18 | $5.46 | +229.67% | 1 | Jul 3, 2024 | |
| CALT Calliditas Therapeutics AB | Downgrades: Hold | $55 → $40 | $40.00 | - | 2 | May 28, 2024 | |
| PHAT Phathom Pharmaceuticals | Initiates: Buy | $24 | $18.30 | +31.15% | 1 | May 3, 2024 | |
| RGNX REGENXBIO | Maintains: Buy | $40 | $12.84 | +211.53% | 2 | Apr 12, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $80 | $66.73 | +19.89% | 6 | Mar 15, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $225 → $230 | $108.79 | +111.42% | 8 | Mar 15, 2024 | |
| EOLS Evolus | Reiterates: Buy | $23 → $25 | $17.49 | +42.94% | 1 | Mar 8, 2024 | |
| IVA Inventiva | Maintains: Buy | $27 → $25 | $2.24 | +1,016.07% | 2 | Feb 16, 2024 | |
| OCS Oculis Holding AG | Initiates: Buy | $35 | $11.94 | +193.13% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $65 | $37.62 | +72.78% | 3 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $0.26 | +10,566.67% | 2 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $28 → $11 | $0.47 | +2,240.43% | 3 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $11.76 | +282.65% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $1.23 | +550.41% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $2.37 | - | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $16.54 | - | 1 | Apr 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $1.79 | - | 2 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $24 | $31.11 | -22.85% | 7 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $15 → $21 | $1.51 | +1,290.73% | 6 | Sep 18, 2019 |
Revance Therapeutics
Aug 9, 2024
Maintains: Buy
Price Target: $24 → $20
Current: $6.55
Upside: +205.34%
Kamada
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $5.46
Upside: +229.67%
Calliditas Therapeutics AB
May 28, 2024
Downgrades: Hold
Price Target: $55 → $40
Current: $40.00
Upside: -
Phathom Pharmaceuticals
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $18.30
Upside: +31.15%
REGENXBIO
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $12.84
Upside: +211.53%
Viking Therapeutics
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $66.73
Upside: +19.89%
Jazz Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $108.79
Upside: +111.42%
Evolus
Mar 8, 2024
Reiterates: Buy
Price Target: $23 → $25
Current: $17.49
Upside: +42.94%
Inventiva
Feb 16, 2024
Maintains: Buy
Price Target: $27 → $25
Current: $2.24
Upside: +1,016.07%
Oculis Holding AG
Oct 5, 2023
Initiates: Buy
Price Target: $35
Current: $11.94
Upside: +193.13%
Aug 29, 2023
Maintains: Buy
Price Target: $60 → $65
Current: $37.62
Upside: +72.78%
Jun 27, 2023
Reiterates: Buy
Price Target: $28
Current: $0.26
Upside: +10,566.67%
Jun 26, 2023
Downgrades: Hold
Price Target: $28 → $11
Current: $0.47
Upside: +2,240.43%
Mar 7, 2023
Initiates: Buy
Price Target: $45
Current: $11.76
Upside: +282.65%
Nov 10, 2022
Upgrades: Buy
Price Target: $8
Current: $1.23
Upside: +550.41%
Aug 24, 2021
Initiates: Buy
Price Target: n/a
Current: $2.37
Upside: -
Apr 24, 2020
Initiates: Hold
Price Target: n/a
Current: $16.54
Upside: -
Apr 16, 2020
Maintains: Buy
Price Target: n/a
Current: $1.79
Upside: -
Apr 16, 2020
Maintains: Hold
Price Target: $25 → $24
Current: $31.11
Upside: -22.85%
Sep 18, 2019
Maintains: Hold
Price Target: $15 → $21
Current: $1.51
Upside: +1,290.73%